Russell Investments Group
TAK icon

Russell Investments Group’s Takeda Pharmaceutical TAK Stock Holding History

Russell Investments Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Buy
152,678
+23,130
+18% +$383K ﹤0.01% 1962
2026
Q1 		$2.4M Buy
129,548
+29,566
+30% +$519K ﹤0.01% 1779
2025
Q4 		$1.56M Buy
99,982
+4,716
+5% +$67.4K ﹤0.01% 2006
2025
Q3 		$1.39M Buy
95,266
+12,205
+15% +$181K ﹤0.01% 2047
2025
Q2 		$1.28M Buy
83,061
+18,598
+29% +$275K ﹤0.01% 1938
2025
Q1 		$959K Buy
64,463
+19,139
+42% +$268K ﹤0.01% 2053
2024
Q4 		$600K Buy
45,324
+14,831
+49% +$204K ﹤0.01% 2215
2024
Q3 		$434K Buy
30,493
+13,036
+75% +$185K ﹤0.01% 2318
2024
Q2 		$226K Buy
17,457
+6,781
+64% +$89.8K ﹤0.01% 2448
2024
Q1 		$148K Buy
10,676
+4,213
+65% +$61.3K ﹤0.01% 2510
2023
Q4 		$92.2K Sell
6,463
-1,059
-14% -$15K ﹤0.01% 2568
2023
Q3 		$116K Sell
7,522
-526
-7% -$8.14K ﹤0.01% 2596
2023
Q2 		$126K Buy
8,048
+1,014
+14% +$16.6K ﹤0.01% 2561
2023
Q1 		$116K Sell
7,034
-99,028
-93% -$1.58M ﹤0.01% 2565
2022
Q4 		$1.65M Hold
106,062
– – ﹤0.01% 1707
2022
Q3 		$1.38M Sell
106,062
-314,313
-75% -$4.37M ﹤0.01% 1771
2022
Q2 		$5.9M Buy
420,375
+51,362
+14% +$733K 0.01% 1018
2022
Q1 		$5.28M Sell
369,013
-11,955
-3% -$176K 0.01% 1125
2021
Q4 		$5.19M Buy
380,968
+7,465
+2% +$105K 0.01% 1229
2021
Q3 		$6.12M Buy
373,503
+155,351
+71% +$2.61M 0.01% 1134
2021
Q2 		$3.67M Buy
+218,152
New +$3.71M 0.01% 1548
2020
Q3 		– Sell
-16,124
Closed -$289K – 3255
2020
Q2 		$289K Buy
+16,124
New +$289K ﹤0.01% 2589
2019
Q1 		– Sell
-26,395
Closed -$444K – 3008
2018
Q4 		$444K Buy
+26,395
New +$446K ﹤0.01% 2361

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Russell Investments Group's TAK Position: Q2 2026 in Review

Russell Investments Group increased its Takeda Pharmaceutical (TAK) stake by 18% in Q2 2026, buying an estimated $383K and bringing the position to 152,678 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1962.

Russell Investments Group first reported a position in TAK in Q4 2018 and has held it in 23 quarters since. The position peaked at $6.12M in Q3 2021. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Russell Investments Group held 152,678 shares of Takeda Pharmaceutical worth $2.45M as of Q2 2026.
  • Russell Investments Group bought 23,130 Takeda Pharmaceutical shares in Q2 2026, an estimated $383K.
  • Takeda Pharmaceutical made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1962 holding.
  • Russell Investments Group first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 23 quarters since.
  • Russell Investments Group's Takeda Pharmaceutical position peaked at $6.12M in Q3 2021.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.